Commentary on Long-term Effectiveness of Adjuvant Treatment in Parkinson Disease-Reply

Richard Gray¹, Crispin Jenkinson¹, Carl E Clarke^{2

3}

Affiliations

¹ Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
² Birmingham Clinical Trials Unit, Institute of Applied Health Research, University of Birmingham, Birmingham, United Kingdom.
³ Department of Neurology, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom.

Comment

Richard Gray et al. JAMA Neurol. 2022.

. 2022 Jul 1;79(7):726-727.

doi: 10.1001/jamaneurol.2022.1604.

Richard Gray¹, Crispin Jenkinson¹, Carl E Clarke^{2

3}

¹ Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
² Birmingham Clinical Trials Unit, Institute of Applied Health Research, University of Birmingham, Birmingham, United Kingdom.
³ Department of Neurology, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom.

No abstract available

Comment on

Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial.
Gray R, Patel S, Ives N, Rick C, Woolley R, Muzerengi S, Gray A, Jenkinson C, McIntosh E, Wheatley K, Williams A, Clarke CE; PD MED Collaborative Group. Gray R, et al. JAMA Neurol. 2022 Feb 1;79(2):131-140. doi: 10.1001/jamaneurol.2021.4736. JAMA Neurol. 2022. PMID: 34962574 Free PMC article. Clinical Trial.
Commentary on Long-term Effectiveness of Adjuvant Treatment in Parkinson Disease.
Gros P, Fox SH, Lang AE. Gros P, et al. JAMA Neurol. 2022 Jul 1;79(7):726. doi: 10.1001/jamaneurol.2022.1601. JAMA Neurol. 2022. PMID: 35759267 No abstract available.